These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 28674134)
21. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA. Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359 [TBL] [Abstract][Full Text] [Related]
22. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease. Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638 [TBL] [Abstract][Full Text] [Related]
23. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084 [TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients. Aliyev ER; Hay JW; Hwang C Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265 [TBL] [Abstract][Full Text] [Related]
25. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334 [TBL] [Abstract][Full Text] [Related]
26. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419 [TBL] [Abstract][Full Text] [Related]
27. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab. Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070 [TBL] [Abstract][Full Text] [Related]
28. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Verstockt B; Moors G; Bian S; Van Stappen T; Van Assche G; Vermeire S; Gils A; Ferrante M Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889 [TBL] [Abstract][Full Text] [Related]
29. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB. Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043 [TBL] [Abstract][Full Text] [Related]
30. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease. Yoshihara T; Shinzaki S; Kawai S; Fujii H; Iwatani S; Yamaguchi T; Araki M; Hiyama S; Inoue T; Hayashi Y; Watabe K; Iijima H; Takehara T Inflamm Bowel Dis; 2017 Dec; 23(12):2172-2179. PubMed ID: 28945638 [TBL] [Abstract][Full Text] [Related]
31. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors. Osamura A; Suzuki Y Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921 [TBL] [Abstract][Full Text] [Related]
32. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of Tumour Necrosis Factor-alpha therapy in paediatric Crohn's disease patients with perianal lesions: a systematic review. Carnovale C; Maffioli A; Zaffaroni G; Mazhar F; Battini V; Mosini G; Pozzi M; Radice S; Clementi E; Danelli P Expert Opin Biol Ther; 2020 Mar; 20(3):239-251. PubMed ID: 31971447 [No Abstract] [Full Text] [Related]
34. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119 [TBL] [Abstract][Full Text] [Related]
35. Lack of anti-TNF drugs levels in fistula tissue - a reason for nonresponse in Crohn's perianal fistulating disease? Adegbola SO; Sarafian M; Sahnan K; Pechlivanis A; Phillips RKS; Warusavitarne J; Faiz O; Haddow J; Knowles C; Tozer P; Holmes E; Hart A Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):18-26. PubMed ID: 33522723 [TBL] [Abstract][Full Text] [Related]
36. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors. Fay S; Ungar B; Paul S; Levartovsky A; Yavzori M; Fudim E; Picard O; Eliakim R; Ben-Horin S; Roblin X; Kopylov U Inflamm Bowel Dis; 2017 Nov; 23(11):1924-1929. PubMed ID: 28837524 [TBL] [Abstract][Full Text] [Related]